The 2 DG drug, like glucose, spreads through the body, reaches the virus-infected cells and prevents virus growth by stopping viral synthesis and destroys the protein’s energy production. The drug also works on virus infection spread into lungs which help us to decrease patients dependability on oxygen.
2-Deoxy-d-glucose is a glucose molecule which has the 2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. As such; it acts to competitively inhibit the production of glucose-6-phosphate from glucose at the phosphoglucoisomerase level .
The authors suggest that 2-DG works, in part, by increasing the expression of Brain-derived neurotrophic factor (BDNF), Nerve growth factor (NGF), Arc (protein) (ARC), and Basic fibroblast growth factor (FGF2).
In November, the Food and Drug Administration authorized emergency use of the monoclonal antibodies for treating patients with mild or moderate COVID-19 who are at high risk of developing more severe disease that requires hospitalization. Clinical trial data as well as anecdotal information from communities suggest that the monoclonal antibodies might prevent the worsening of symptoms and keep patients out of the hospital.
The US Department of Health and Human Services has signed agreements with Regeneron to buy about 300 000 courses of its casirivimab and imdevimab combination treatment and with Eli Lilly and Company to buy about 3 million courses of its bamlanivimab therapy if needed.